Natco Pharma Ltd.

Natco Pharma has received marketing approval for its Rizatriptan Benzoate (Maxalt-MLD) orally disintegrating tablets, 5 mg and 10 mg (base) from US Food & Drug Administration (USFDA). The Company has already commenced shipments of the product, which is being launched by its marketing partner - Breckenridge Pharmaceuticals.

Rizatriptan is used to treat migraine headaches with or without aura (warning signs that occur prior to the onset of a migraine headache). The company is estimating the market to be around $250 million (before generic launch - as of December, 2012).

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh.